Figure 5
From: c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma
SU11274 treatment significantly reduced tumor growth in an orthotopic OCCC mouse model with RMG1.
(A) Experimental outline for orthotopic OCCC mouse model. (B) The SU11274-treated group (n = 10) had significantly lower tumor weights compared with the PBS-injected control group (n = 10). (C) The SU11274-treated group showed reduced phospho-c-MET expression compared with the control group. (D) Tumor cell proliferation as assessed by Ki67 immunohistochemistry in harvested tumor tissues was significantly lower in the SU11274-treated group (n = 5). (E) TUNEL assay indicated significantly higher apoptosis in the SU11274-treated group (error bar represents s.e.m., *p < 0.010).
